Spots Global Cancer Trial Database for Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Lenalidomide in Treating Patients With Advanced or Unresectable Kidney Cancer

Official Title: Phase II Study of CC-5013 in Patients With Advanced Renal Cell Carcinoma (RCC)

Study ID: NCT00403169

Conditions

Kidney Cancer

Interventions

lenalidomide

Study Description

Brief Summary: RATIONALE: Lenalidomide may stop the growth of kidney cancer by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients with advanced or unresectable kidney cancer.

Detailed Description: OBJECTIVES: * Evaluate the best response in patients with advanced or unresectable renal cell carcinoma (RCC) treated with lenalidomide. * Evaluate the response duration, time to tumor progression, and survival of patients with advanced RCC treated with lenalidomide. * Evaluate the safety of this drug in these patients. OUTLINE: This is an open-label study. Patients receive oral lenalidomide daily on days 1-21. Courses repeat every 28 days in the absence of unacceptable toxicity or disease progression. After completion of study treatment, patients are followed every 3 months. PROJECTED ACCRUAL: A total of 26 patients will be accrued for this study.